

2-1-1995

Non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF) treatment for patients with febrile neutropenia following chemotherapy

Narin Voravud

Virote Sriuranpong

Nuchara Nithipaijit

Navapun Charuruks

Follow this and additional works at: <https://digital.car.chula.ac.th/clmjjournal>



Part of the [Medicine and Health Sciences Commons](#)

Recommended Citation

Voravud, Narin; Sriuranpong, Virote; Nithipaijit, Nuchara; and Charuruks, Navapun (1995) "Non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF) treatment for patients with febrile neutropenia following chemotherapy," *Chulalongkorn Medical Journal*: Vol. 39: Iss. 2, Article 5.

Available at: <https://digital.car.chula.ac.th/clmjjournal/vol39/iss2/5>

This Article is brought to you for free and open access by the Chulalongkorn Journal Online (CUJO) at Chula Digital Collections. It has been accepted for inclusion in Chulalongkorn Medical Journal by an authorized editor of Chula Digital Collections. For more information, please contact ChulaDC@car.chula.ac.th.

Non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF) treatment for patients with febrile neutropenia following chemotherapy.

Narin Voravud* Virote Sriuranpong*
Nuchara Nithipaijit* Navapun Charuruks**

Voravud N, Sriuranpong V, Nithipaijit N, Charuruks N. Non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF) treatment for patients with febrile neutropenia following chemotherapy. *Chula Med J* 1995 Feb; 39(2): 107-118

Febrile neutropenia after chemotherapy administration in cancer patients contribute to significant morbidity and mortality. Current therapy is prompt empirical antibiotics for this condition. Prognosis depends on several factors especially severity and duration of neutropenia. rhG-CSF is a growth factor for neutrophils. Utilization of rhG-CSF to accelerate neutrophil production during neutropenia and infection may decrease severity and consequence of the afore-mentioned condition. Therefore, we studied therapeutic efficacy of rhG-CSF in combination with antibiotics and compared with antibiotics alone in cancer patients who developed febrile neutropenia after chemotherapy. It was found that rhG-CSF can reduce mortality rate from infection (32% VS 7%, $p=0.004$), and incidence of septic shock (36% VS 11.1%, $p=0.009$). However, no statistical difference between the two groups when compared duration of fever, absolute granulocyte count, duration of antibiotics and days of hospitalization. Median absolute granulocyte count nadir was not different between the two treatment groups ($180/\text{mm}^3$ VS $200/\text{mm}^3$, $p=0.630$). Side effects of rhG-CSF were myalgia (22.1%) and bone pain (12.9%). The use of rhG-CSF in combination with antibiotics in the management of febrile neutropenia after chemotherapy can effectively decrease mortality rate and incidence of septic shock with only mild side effects.

Key words : Colony stimulating factor, Antineoplastic agents, Febrile neutropenia.

Reprint request : Voravud N., Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.

Received for publication. January 3, 1995.

*Department of Medicine, Faculty of Medicine, Chulalongkorn University.

**Department of Laboratory Medicine, Faculty of Medicine, Chulalongkorn University.

นรินทร์ วรฤติ, วิโรจน์ ศรีอุฬารพงศ์, นุชรา นิธิไพจิตร, นวพรรณ จารุรักษ์. นอน-ไกลโคไซเลทเทต รีคอมบิเนนท์ ฮิวแมน แกรนนูโลไซท์ โคลโลนี-สติมูเลติง แฟคเตอร์ (อาร์เฮซจี-ซีเอสเอฟ) ในการรักษาผู้ป่วยที่มีไข้และภาวะเม็ดเลือดขาวต่ำหลังได้รับยาเคมีบำบัด. จุฬาลงกรณ์เวชสาร 2538 กุมภาพันธ์; 39(2): 107-118

ภาวะไข้ร่วมกับเม็ดเลือดขาวต่ำหลังได้รับยาเคมีบำบัดเป็นผลข้างเคียงที่พบบ่อยในผู้ป่วยมะเร็งซึ่งก่อให้เกิดผลแทรกซ้อนและอัตราการตายสูง การรักษาที่ใช้อยู่ในปัจจุบันคือการให้ยาปฏิชีวนะเมื่อเกิดภาวะนี้ขึ้น การพยากรณ์โรคขึ้นอยู่กับปัจจัยหลายอย่างโดยเฉพาะความรุนแรง และระยะเวลาที่เม็ดเลือดขาวต่ำ rhG-CSF เป็นสารที่กระตุ้นการสร้างเม็ดเลือดขาว neutrophils การให้ rhG-CSF เพื่อเพิ่มการสร้างเม็ดเลือด neutrophils ในภาวะที่เม็ดเลือดขาวตกต่ำและมีการติดเชื้ออาจช่วยลดความรุนแรง และผลข้างเคียงของภาวะดังกล่าวได้ ดังนั้น คณะผู้วิจัยได้ศึกษาผลของการใช้ rhG-CSF ร่วมกับยาปฏิชีวนะเปรียบเทียบกับการใช้ยาปฏิชีวนะในผู้ป่วยมะเร็งที่เกิดไข้นะที่เม็ดเลือดขาวต่ำหลังได้ยาเคมีบำบัด พบว่า rhG-CSF สามารถลดอัตราการตายจากการติดเชื้อ (32% VS 7%, $p = 0.004$) และภาวะช็อคจากโรคติดเชื้อ (36% VS 11.1%, $p = 0.009$) แต่ไม่พบความแตกต่างระหว่างทั้งสองกลุ่ม เมื่อเปรียบเทียบระยะเวลาเฉลี่ยของการมีไข้, จำนวนเม็ดเลือดขาวต่ำ, การได้ยาปฏิชีวนะ และระยะเวลาการอยู่ในโรงพยาบาล จำนวนเม็ดเลือดขาวที่ต่ำที่สุดของทั้งสองกลุ่มไม่แตกต่างกัน ($180/\text{mm}^3$ VS $200/\text{mm}^3$, $p = 0.630$) ผลข้างเคียงของ rhG-CSF คืออาการปวดเมื่อยกล้ามเนื้อ (22.1%) และปวดกระดูก (12.9%) การใช้ rhG-CSF ร่วมกับยาปฏิชีวนะในการรักษาภาวะไข้นะที่เม็ดเลือดขาวต่ำหลังได้ยาเคมีบำบัดในผู้ป่วยมะเร็ง สามารถลดอัตราการตายและภาวะช็อคจากโรคติดเชื้อได้อย่างมีประสิทธิภาพ และมีผลข้างเคียงจากยาน้อย

Recently, considerable progress has been made in the management of cancer, including the use of new antineoplastic agents and regimens. The development of intensive antitumor regimens with potential cure for some malignancies has led to severe and prolonged chemotherapy-induced cytopenia. With increasing dose intensity of chemotherapy, neutropenia becomes the most common dose-limiting toxicity of cytotoxic regimens. Consequently, the risk of infection following chemotherapy-induced neutropenia increases proportionally to the depth and duration of neutropenia.⁽¹⁾ Infection in the neutropenic cancer patient presents a number of problems including high morbidity and mortality rates from such sequelae. Death from infection in a setting of granulocytopenia is not infrequent and the morbidity and economic cost associated with non-fatal infection is usually substantial. Moreover, it is frequently necessary to reduce the dosage of chemotherapy and to delay the next treatment until after the patient recovers from the febrile neutropenia. The compromising effects of dose reduction and delay of chemotherapy on the therapeutic outcome are enormous. In vitro and in vivo studies in a wide range of malignant diseases have supported the importance of the dose intensity of chemotherapy as a major determinant of tumor response which will contribute to better response rate and survival rate.⁽²⁾ Therefore, an inability to deliver a proper dose of chemotherapy on schedule owing to the development of febrile neutropenia may substantially compromise the response and survival of cancer patients.

Because of the magnitude of this problem, prompt diagnosis and empirical antibacterial therapy in the febrile, neutropenic patient with neoplastic disease has become standard. In spite

of the initiation of broad-spectrum intravenous antibiotics, death from sepsis ranges from 5-20%.⁽³⁾ The most important factor in determining the outcome of infection in the febrile, neutropenic patients is the severity and duration of neutropenia. If the nadir absolute granulocyte count (AGC) falls below 1000, 500 and 100/mm³, the frequency of life-threatening infection rises steeply from 10% to 19% and 28%, respectively. Patients with severe neutropenia which had persisted for longer than 3 weeks had a 60% chance of developing severe infection⁽¹⁾. Therefore, one therapeutic approach to decrease the morbidity and mortality from chemotherapy-induced febrile neutropenia is to administer a growth factor that can accelerate the production of polymorphonuclear cells from the bone marrow.

Granulocyte colony-stimulating factor (G-CSF) is a human glycoprotein which acts primarily to stimulate proliferation, differentiation, maturation, and function of neutrophils. Recombinant human granulocyte colony-stimulating factor (rhG-CSF) has been produced by introducing a cDNA encoding the human gene into *Escherichia coli*. It consists of 175 amino acids and differs from the endogenous protein in two respects. Firstly, it has methionine as a terminal amino acid. Secondly, it is not glycosylated secondary to being expressed in *E. coli*. Nevertheless, its activities are similar to the natural glycosylated G-CSF.⁽⁴⁾ In vitro and in vivo data showed that rhG-CSF leads to the increase in absolute neutrophil count (ANC) in peripheral blood of normal volunteers and cancer patients who received myelosuppressive agents. The rhG-CSF has a beneficial effect to reduce the incidence of febrile neutropenia from 57 to 28%

when used as primary prophylaxis of chemotherapy-induced neutropenia.⁽⁵⁾

Despite the effectiveness of rhG-CSF in the prevention of chemotherapy-induced febrile neutropenia, the therapeutic efficacy of rhG-CSF in the treatment of febrile neutropenia is unclear. Therefore, we conducted a prospective open-labelled phase II study of rhG-CSF in the management of chemotherapy-induced febrile neutropenia. The objectives of the study were to evaluate (1) the efficacy of rhG-CSF in the treatment of infection in cancer patients with chemotherapy-induced neutropenia, and (2) the toxicity of rhG-CSF given in this fashion.

Patients and Methods

All of the cancer patients in this prospective study developed febrile neutropenia after receiving cytotoxic chemotherapy. Febrile neutropenia was defined as a body temperature of 38.5°C or greater, presumed or proved to have infection, and an absolute neutrophil count of less than 1,000 /mm³ following myelosuppressive chemotherapy.

Preparation of recombinant human granulocyte colony-stimulating factor(rhG-CSF)

The study drug, non glycosylated rhG-CSF (Neupogen^R), is a human glycoprotein produced in *Escherichia coli* by recombinant-DNA technology. It has 175 amino acids with a molecular weight of 18,800 and is non-glycosylated. The product is a clear, colorless, sterile solution with a concentration of 300 ug of protein per milliliter. The specific activity of the recombinant protein is 1x10⁸ per milligram of protein. Production of the medication was partly supported by the Roche Pharmaceutical Co, Thailand.

Eligibility

Patients were eligible for enrollment in the study if they had histological or cytological proven non-hematologic malignancies. All eligible patients developed fever of over 38.5°C and had absolute neutrophil counts of less than 1,000/mm³ following myelosuppressive antineoplastic agents. All patients had normal renal and hepatic functions, no other serious medical illness that precluded participation, and no history of autoimmune disease.

Study Design

This study was designed as an open-label phase II study of both the safety and efficacy of rhG-CSF in the treatment of cancer patients with fever and neutropenia. All of the patients enrolled in the study had to be admitted to the hospital. After microbiologic study, the patients received 5 ug/kg/day of rhG-CSF given subcutaneously once daily until ANC over 10,000 /mm³ and beyond nadir period. Empirical antibiotics consisting of 25 mg/kg/doses of ceftazidime given intravenously every 8 hours and 7.5 mg/kg/doses of amikacin given intravenously every 12 hours were given at the onset of febrile neutropenia after the diagnosis of microbiologic studies. The patients with positive culture or specific sites of infection received antibiotics according to the clinical evidence of infection depending on the physician's judgement.

The initial assessments included complete history and physical examination. Pretreatment laboratory investigations consisted of a complete blood count with differential and platelet count, liver and renal function studies. Physical examinations were performed regularly throughout the study period. Complete blood counts were

Table 1. Patient Characteristics.

	rhG-CSF used	No rhG-CSF
Total No. of patients	40	22
Total episodes of febrile neutropenia	54	25
Sex		
Male : Female	19:21	9:13
Median age	55	50
rang	40-76	19-77
Performance status(Zubord) (episodes)		
1	12(22%)	3(12%)
2	24(45%)	10(40%)
3	18(33%)	12(48%)
Diagnosis (number of patients)		
head and neck cancer	6	-
lung cancer : non small cell	8	4
: small cell	3	2
breast cancer	6	3
digestive : hepatocellular carcinoma	2	1
: cholangio carcinoma	-	1
gastrointestinal cancer : stomach	1	1
: colorectal	5	4
genitourinary : bladder	1	1
germ cell tumor	-	3
ovary	1	-
sarcoma	5	2
unknown primary	2	-
concomitant chemoradiation	6	2
Mean hematologic prestudy value (per mm ³)		
total WBC	850	1,020
absolute neutrophil count	215(26-960)	350(100-960)

Table 2. Malignancy and Chemotherapy regimens.

Malignancy	Chemotherapy regimens	rhG-CSF used (episodes)	No rhG-CSF (episodes)
Lung	Carboplatin, Etoposide	5	5
	Epirubicin, Cyclophosphamide, Etoposide	1	1
	Cisplatin, Mitomycin C, Vincristine	3	1
	Cisplatin, Etoposide	1	1
	Paclitaxel	3	-
	Etoposide	2	1
Head and Neck	Cisplatin, Epirubicin	2	-
	Cisplatin, Epirubicin, Bleomycin	3	-
	Ifosfamide	2	-
Breast	5FU, Cyclophosphamide, Epirubicin	3	-
	5FU, Cyclophosphamide, Methotrexate	2	2
	5FU, Carboplatin,	1	-
	Ifosfamide, Mitoxantone	1	1
Hepatoma and Cholangio carcinoma	Epirubicin	1	2
	Chemoembolization (5FU, Mitomycin C)	1	-
Stomach	5FU, Etoposide, Leucovorin	2	1
	5FU, Cisplatin, Epirubicin, Leucovorin	1	-
Colorectal	5FU, Interferon	3	2
	5FU, Leucovorin	1	2
	Cisplatin, 5FU	1	-
Germ cell	Cisplatin, Etoposide, Bleomycin	-	1
	Doxorubicin, Vincristine, Cyclophosphamide, Bleomycin, Cisplatin	-	2
Sarcoma	Ifosfamide, Etoposide	6	-
	Ifosfamide, Epirubicin	2	1
	Ifosfamide, Doxorubicin, Vincristine, Cisplatin	1	-
	Ifosfamide, Epirubicin, Vincristine	-	1
	Methotrexate (high dose)	1	-
Ovary	Ifosfamide	1	-
Bladder	Cisplatin, 5FU, Interferon	1	-
	5FU, Interferon	1	1
Unknown Primary	Paclitaxel	3	-

The therapeutic efficacy of rhG-CSF in the management of chemotherapy-induced febrile neutropenia is shown in Table 3. Septic shock as a severe complication of febrile neutropenia developed in 6 of 54 episodes (11.1%) in the rhG-CSF treated group and 9 of 25 episodes (36%) of control group ($p=0.009$). This sequel contributed to a mortality rate of 7% and 32%, respectively ($p=0.004$). The duration of neutropenia was expressed as the number of days of absolute granulocyte count below $1,000/\text{mm}^3$.

There was no difference in the median duration of neutropenia ($p = 0.16$), fever ($p = 0.33$), antibiotic treatment ($p = 0.22$), and hospitalization ($p = 0.52$) between the rhG-CSF and control groups. The shorter than expected duration of these parameters which was observed in the control group may be related to the higher mortality rate of this group. The median absolute nadir granulocyte count was $180/\text{mm}^3$ (range 20-950) in the rhG-CSF treated group versus $200/\text{mm}^3$ (range 10-900) in the control group ($p = 0.63$).

Table 3. Result of treatment.

	rhG-CSF used	No rhG-CSF	P value
Septic shock (episodes)	6(11.1%)	9(36%)	0.009*
Dead from sepsis(episodes)	4(7.4%)	8(32%)	0.004*
Median Duration of : (days)			
: fever	4.5(1-49)	5(1-30)	0.332
: neutropenia (AGC<1,000/mm ³)	4(1-13)	4(1-10)	0.159
: neutropenia (AGC <500/mm ³)	2(0-13)	3(0-14)	0.049*
: antibiotics treatment	8(2-32)	7.5(1-18)	0.218
: rhG-CSF treatment	5(1-18)	-	-
: hospitalization	10(2-35)	11(3-19)	0.519
AGC nadir (per mm ³)	180(20-950)	200(10-600)	0.630

*Statistical significant.

Etiology of infection was found in 19 episodes (24%) of febrile neutropenia; twelve episodes (22.2%) in the rhG-CSF group and 7 episodes (28%) of the control group, as shown in

Table 4. The majority of infections were gram negative bacilli. *Pseudomonas aeruginosa* was an uncommon organism seen in only 2 cases only, 1 in the rhG-CSF and 1 in the control group.

onset of febrile neutropenia may shorten the duration of neutropenia, and enhance neutrophil function with consequent reductions in infectious morbidity and mortality.

In our study, a significant reduction in infectious mortality was observed in the rhG-CSF treated group when compared to the control group (7% versus 32% $p = .004$). Although the reduction of mortality supported the use of rhG-CSF as an adjunct to antibiotic therapy, other clinical parameters of neutrophil recovery (fever duration, time on antibiotics, duration of hospitalization) were not significantly shortened with the rhG-CSF treatment. Two randomized controlled trials have evaluated rhG-CSF as an adjunctive therapy for patients with chemotherapy-induced neutropenia. The rhG-CSF increased recovery from neutropenia in both trials,^(11,12) and decreased the duration of antibiotic therapy and hospitalization in one trial.⁽¹²⁾ The infectious mortality rate was low in both the G-CSF treated and placebo groups and the mortality rate was unaffected by rhG-CSF treatment. Conversely, our study revealed a high mortality rate of 32% in the control group. When rhG-CSF was given as an adjunct to antibiotics it significantly decreased infectious mortality (Table 6). While there is variability in the outcomes among the studies, these discrepancies seem to arise from differences in study design, malignancy types and antineoplastic regimens. Recent studies suggested that patients with protracted neutropenia or evidence of tissue infection may have the greatest chance of benefit from the addition of CSF.⁽¹³⁾

The toxicity of rhG-CSF given to patients with febrile neutropenia was mild and well tolerated. Side effects consisted of myalgia, bone pain, and malaise. No discontinuation of rhG-CSF occurred during the study.

The majority of the infectious organisms were gram negative bacilli. Only 4 episodes of the rhG-CSF group and 2 episodes of the control group were gram positive cocci including *Staphylococcus aureus* and *Staphylococcus epidermidis*. *Pseudomonas aeruginosa* was uncommon in our series. This may be explained by the fact that our study did not include leukemia patients who have frequently been reported to be associated with *P.aeruginosa* bacteremia.⁽¹⁴⁾ The low incidence of gram positive bacterial infection may be related to the use of the peripheral intravenous line instead of the central venous line for chemotherapy administration in our patients.⁽¹⁵⁾

The hematopoietic colony-stimulating factor has been introduced into clinical practical practice as an additional supportive measure that can reduce the likelihood of neutropenic complication due to chemotherapy. Although clinical benefit has been shown in the prevention of chemotherapy-associated neutropenic fever or infection,^(16,17) its therapeutic efficacy in the treatment of febrile neutropenia following chemotherapy is not yet well established. Moreover, the high cost of CSF has led to concern about its appropriate use. The therapeutic initiation of CSF, in addition to antibiotics at the onset of febrile neutropenia, should be reserved for patients at high risk for septic complications.^(13,15,18,19) Our data suggests that the use of rhG-CSF with antibiotics for patients with febrile neutropenia following chemotherapy warrants prospective randomized double blind placebo, controlled trials to determine therapeutic efficacy, the cost-effectiveness of administration of rhG-CSF⁽¹⁹⁾ and to identify clinical predictors of infectious complications that may direct its use in the management of febrile neutropenia.

References

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. *Ann Intern Med* 1966 Feb; 64(2):328-40
2. Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. *J Clin Oncol* 1986 Aug; 4(8):1162-70
3. Ozer H. Clinical Implication of Neutropenia in Patients Receiving Cytotoxic Chemotherapy. *Clinician* 1992 Apr; 10(3):2-12
4. Voravud N. Granulocyte colony-stimulating factors. Biology and clinical application. In : Maireung P. ed. *Update in Internal Medicine Khonkaen, Klungwitaya.* 1993; 152-65
5. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy patients with small-cell lung cancer. *N Engl J Med* 1991 Jul 18; 325(3):164-70
6. Cameron BR.eds. *Practical Oncology: a Lange clinical manual.* 1st ed. Connecticut: Appleton & Lange. 1994: 661-662
7. Schimpff SC. Overview of empirical antibiotic therapy for the febrile neutropenia patient. *Rev Infect Dis* 1985 Nov-Dec; 7 Suppl 4: S734-S740
8. Schimpff SC, Yong VM, Greene WH, Vermeulen GD, Moody MR, Wiernik PH. Origin of infection in acute nonlymphocytic leukemia: significance of hospital acquisition of potential pathogens. *Ann Intern Med* 1972 Nov; 77(5): 707-14
9. Klustersky J, Zinner SH. Synergistic combinations of antibiotics in gram-negative bacillary infections. *Rev Infect Dis* 1982 Jul-Aug; 4(2):294-301
10. Love LJ, Schimpff SC, Schiffer CA, Wiernik PH. Improved prognosis for granulocytopenic patients with gram-negative bacteremia. *Am J Med* 1980 May; 68(5): 643-8
11. Maher D, Green m, Bishop J. Randomized, placebo controlled trials of filgrastim (r-metHuG-CSF) in patients with febrile neutropenia(FN) following chemotherapy (CT). *Proc Am Soc Clin Oncol* 1993; 12:434(Abstr)
12. Mayordomo JI, Rivera F, Diaz-Puente MT. Decreasing morbidity and cost of treating febrile neutropenia by adding G-CSF and GM-CSF to standard antibiotic therapy: results of a randomized trial. *Proc Am Soc Clin Oncol* 1993; 12:437(Abstr)
13. American Society of Clinical Oncology. Recommendation for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. *J Clin Oncol* 1994 Nov; 12(11):2471-508
14. Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. *Arch Intern Med* 1985 Sep; 145(9):1621-9
15. Pizzo PA, Ladisch S, Simon RM, Gill F, Levine AS. Increasing incidence of gram-positive sepsis in cancer patients. *Med Pediatr Oncol* 1978; 5(1):241-4
16. Voravud N, Nithipaichit N, Foofung S. Non-glycosylated recombinant human granulocyte-colony stimulating factor in primary prophylaxis of chemotherapy-in-

- duced neutropenia. Proceeding 35th Annual Scientific Meeting, Chulalongkorn University. 1994, 115-116
7. Voravud N, Nithipaichit N, Sriuranpong V, Jaruruk N, Foofung S. Secondary prophylaxis of chemotherapy-induced neutropenia by recombinant human granulocyte-colony stimulating factor (rhG-CSF). Proceeding 36th Annual Scientific Meeting, Chulalongkorn University. 1995, 168-170
18. Yong RC, Bennett JE, Vogel CL, Carbone PP, DeVita VT. Aspergillosis. The spectrum of the disease in 98 patients. *Medicine* 1970 Mar; 49(2):147-73
19. Edwards JE, Lehrer RI, Stiehm ER, Fischer TJ, Young LS. Severe candidal infections: clinical perspective, immune defence mechanisms, and current concepts of therapy. *Ann Intern Med* 1978 Jul; 89(1):91-106
20. Faulds D, Lewis N JW, Milne RJ. Recombinant granulocyte colony-stimulating factor (rG-CSF) pharmacoeconomic consideration in chemotherapy-induced neutropenia. *Pharmacol Econ* 1992 Apr; 1(4):231-49